AFFX Affymetrix, Inc.

Xenogen Elects Gregory T. Schiffman to Board of Directors ALAMEDA, Calif., Jan. 13 /PRNewswire-FirstCall/ -- Xenogen Corporation (NASDAQ:XGEN) today announced the election of Gregory T. Schiffman, MBA, CPA, to its Board of Directors. The election is effective as of January 13. Mr. Schiffman will also join Xenogen's Audit Committee and Nominating & Governance Committee. Mr. Schiffman is the senior vice president and the chief financial officer of Affymetrix Inc. (NASDAQ:AFFX), a pioneer in creating breakthrough tools that are driving the genomic revolution. Mr. Schiffman, who holds an MBA from the Kellogg Graduate School of Management at Northwestern University and a Bachelor of Science degree in accounting from De Paul University, has more than 20 years financial experience, serving in management and controller roles at Applied Biosystems and Hewlett Packard Company prior to joining Affymetrix. "Greg Schiffman's distinguished career and strong financial background will be a valuable asset to the board, and we look forward to benefiting from the expertise he brings," said David Carter, chief executive officer and chairman, Xenogen. "Xenogen is a unique company that has discovered and developed a new research standard in drug development, which improves the productivity and efficiency of the drug discovery and development process," said Mr. Schiffman. "I am thoroughly impressed by Xenogen's technology and seasoned management team, and I look forward to working with the company." Xenogen also announced that Brian Atwood, a co-founder of Versant Ventures, a managing partner of Brentwood Venture Capital, has stepped down from the board after seven years of service to make room for Mr. Schiffman's appointment. "The board and management of Xenogen appreciate Brain's many contributions and will miss the thoughtful guidance he provided as a member of the board," Chairman Carter said. About Xenogen Corporation Xenogen combines systems biology and low-light optical imaging to create powerful new biophotonic imaging technology that advances the ability of scientists to explore genes, proteins, pathogens and tumor cells in living animals in real time, providing predictive data that is designed to substantially improve the success rate in drug development. Xenogen incorporates into living animals the bioluminescent gene that makes a firefly glow and captures the resulting light using an ultra-sensitive camera and sophisticated software. This biophotonic imaging technology creates images and analyzes the data generated on cellular activity, gene expression, spread of disease or the effect of a new drug candidate. Xenogen's biophotonic imaging technology is used by leading academics and pharmaceutical and biotechnology companies to provide more accurate and previously unavailable data intended to result in the ability to make more timely and cost-effective decisions at every step in the drug development process. Xenogen Biosciences, a wholly owned subsidiary of Xenogen, offers more than 14 years of experience in the transgenic field, providing reliable, genetically modified custom mouse models in short timelines. The company has completed more than 2,000 transgenic and 600 gene targeting experiments, with a greater than 95 percent success rate in delivering transgenic founder or gene knockout lines to customers. More information about Xenogen is available on the company's Web site at http://www.xenogen.com/. Xenogen(R), Living Image(R) and IVIS(R) are registered trademarks of Xenogen Corporation. Forward-Looking Statement This press release contains forward-looking statements regarding our imaging products and technologies and their intended uses. These forward-looking statements are based on our current expectations, estimates and assumptions and are subject to many risks, uncertainties and unknown future events that could cause actual results to differ materially. Actual use and results of imaging products and technologies may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: our expectations regarding growth in adoption of our technology and the capital spending policies of pharmaceutical, biotechnology and chemical companies and biomedical research institutions that are our primary customers; our ability to continue to deliver our products on a timely basis; our ability to enforce our intellectual property rights or operate without infringing or misappropriating the proprietary rights of others; and other risk factors set forth in our filings with the Securities and Exchange Commission. For a discussion of these and other factors that could impact the adoption and use of our imaging products and technologies and cause them to differ materially from those in the forward-looking statements, please refer to our recent filings with the Securities and Exchange Commission, including our most recent quarterly report on Form 10-Q. We assume no obligation to update any forward- looking statements or information, which speak as of their respective dates. DATASOURCE: Xenogen Corporation CONTACT: investors, William A. Albright of Xenogen Corporation, +1-510-291-6104; or press, Kelly O'Brien of Manning Selvage & Lee, +1-415-364-3840, for Xenogen Corporation Web site: http://www.xenogen.com/

Copyright